Schering-Plough Expands Antibody Collaboration With Xoma
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal builds on May agreement to discover and develop therapeutic monoclonal antibodies.
You may also be interested in...
Xoma Launches Phase I Trial Of Monoclonal Antibody Diabetes Therapy
Xoma 052 targets interleukin-1 beta to stop destruction of pancreatic cells.
Xoma Launches Phase I Trial Of Monoclonal Antibody Diabetes Therapy
Xoma 052 targets interleukin-1 beta to stop destruction of pancreatic cells.
Takeda Expands Antibody Collaboration With Xoma
Agreement now could earn California company $230 million before royalties for identifying therapeutic antibodies that target cancer.